Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4.5-year results from a phase 3, randomised, double-blind, placebo-controlled trial

Consistency of immunogenicity in three consecutive lots of a tetravalent dengue vaccine candidate (TAK-003): A randomized placebo-controlled trial in US adults

An open-label, phase 3 trial of TAK-003, a live attenuated dengue tetravalent vaccine, in healthy US adults: immunogenicity and safety when administered during the second half of a 24-month shelf-life

Antibodies produced in response to a live-attenuated dengue vaccine are functional in activating the complement system

Bridging the immunogenicity of a tetravalent dengue vaccine (TAK-003) from children and adolescents to adults

Immunogenicity and safety of concomitant and sequential administration of yellow fever YF-17D vaccine and tetravalent dengue vaccine candidate TAK-003: A phase 3 randomized, controlled study

Effect of the tetravalent dengue vaccine TAK-003 on sequential episodes of symptomatic dengue

Rebuttal to de Silva A. Clin Infect Dis. 2023 letter: Safety of dengue vaccine?

A randomized phase 3 trial of the immunogenicity and safety of coadministration of a live-attenuated tetravalent dengue vaccine (TAK-003) and an inactivated hepatitis a (HAV) virus vaccine in a dengue non-endemic country

Clinical safety experience of TAK-003 for dengue fever: a new tetravalent live attenuated vaccine candidate

Rebuttal to de Silva A. J Infect Dis. 2022 letter: Reply to de Silva and White

Neutralization fingerprinting technology for characterizing polyclonal antibody responses to dengue vaccines